Gonadotropin releasing hormone (GnRH) antagonists, such as degarelix, are emerging as an androgen deprivation therapy primary agents in a treatment of advanced prostate cancer.
The role of GnRH antagonists in management of lower urinary tract symptoms associated with prostate cancer has not been clearly established. In this report, we describe the case of a patient with locally advanced prostate cancer who presented with symptoms of urinary retention and renal failure. The use of degarelix in this patient led to a rapid reduction in the prostate-specific antigen level; however, obstructive symptoms persisted despite the use of degarelix and radiation treatment.
Written by:
Ruzhynsky V, Whelan P. Are you the author?
McMaster University, Hamilton, Ontario, Canada.
Reference: Can J Urol. 2013 Jun;20(3):6808-10.
PubMed Abstract
PMID: 23783053
UroToday.com Prostate Cancer Section
